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Abstract: 
Objective: To identify risk factors for anti-tuberculous drugs influence hepatitis (ATDH) among tuberculosis 
patients. 
Study Design: A retrospective study. 
Place and Duration: In the Jinnah Hospital, Lahore in Gastroenterology and Pulmonology department for three 
years period from January 2016 to December 2018 after the approval from the ethical committee of  Jinnah 
Hospital, Lahore 
Methodology: The medical records of tuberculosis 3056 cases were reported for three years was collected and data 
analyzed for ATDH done. TB inclusion criteria identified based on the National Tuberculosis Program (NTP) has 
been documented. ATDH and Non-ATDH data were analyzed in the SPSS version 17 and full fisheries and chi-
square tests. 
Results: 198 cases were diagnosed as ATDH which include 66 (33.01%) women and 134 (66.99%) males, 43.2 
years was the mean age, SD 9.5 treatment and ATDH as follow up period were selected for the study. ATDH in 
patients was found to be significant statistically (p = 0.0001, OR: 13.92) (OR: 7.6, p = 0.0002) and (OR: 11.3, p = 
0.0001) was the difference between intravenous injection ATDH and HIV infection. 
Conclusion: ATDH had the highest prevalence among patients suffering from HCV infection, HIV and IVDU 
infection. 
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INTRODUCTION: 
A major public health issue worldwide is 
Tuberculosis (TB). Mycobacterium tuberculosis 
infect 1/3rd of the world's population, and it is 
estimated that every year 800,000 new cases of 
tuberculosis occur. In Pakistan, it is an important 
cause of mortality and morbidity. National 
Tuberculosis Program (NPT) TB management is 
divided into two phases, isoniazid, rifampicin, 
pyrazinamide and ethambutol are standard 6 months. 
The intensive phase continued with isoniazid and 
rifampicin in the second phase and then two more 
with four drugs. The most serious and common side 
effects of isoniazid, pyrazinamide and rifampicin is 
Hepatotoxicity and may cause these reactions in the 
treatment of tuberculosis. Previous studies have 
shown that patients treated with a standard 
combination therapy against tuberculosis containing 
approximately 10%, isoniazid and rifampicin, 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), such as suddenly rise in 
serum hepatocellular enzymes 1-2% most hepatic 
reactions are attributed to fámaco.8 risk factors 
(ATDH) due to hypersensitivity to antituberculosis 
drugs, but some hepatitis caused by hepatitis. These 
are phenotype, age acetylated, poor nutrition, 
alcoholism, HIV infection and chronic hepatitis B 
infections and ADDH may increase risk. C. Other 
factors are promoted include the co-administration of 
tuberculosis, Asian ethnic, female, eg inducing 
enzymes (anesthetic agents and barbiturates) and 
improper drugs use. Pancreatic liver dysfunction 
usually occurs during the first weeks of intensive 
phase of t tuberculosis treatment. Patient education, 
especially with risk factors for hepatitis symptoms 
and laboratory follow-up (AST and ALT), is 
necessary to enhance the outcome of hepatitis 
patients who are afflicted during TB treatment. This 
study was conducted to determine the risk factors for 
ATDH in TB patients, considering the lack of studies 
on epidemiology to assess ATDH risk factors 
resulting from Ahvaz NPT regimen. 
 
MATERIALS AND METHODS: 
This retrospective study was held in Jinnah Hospital, 
Lahore in Gastroenterology and Pulmonology 
department for three years period from January 2016 
to December 2018 after the approval from the ethical 
committee of Jinnah Hospital, Lahore. The medical 
records of tuberculosis 3056 cases were reported for 
three years was collected and data analyzed for 
ATDH done. TB inclusion criteria identified based 
on the National Tuberculosis Program (NTP) has 
been documented. Criteria for diagnosis for Positive 
pulmonary tuberculosis (PTB +) spread with two 
positive cases for acid-acid bacilli at least (SSP-
ARB), chest radiography suggesting Bacillus or 
tuberculosis plus M. tuberculosis and SSP-defined 
AFB-positive SSP-AFB or marrow culture. Clinical 
findings are defined as TB plus negative pulmonary 
tuberculosis (PTB) antibiotic treatment with more C-
X (implanted TB) and three negative sputum smear 
(SSK-ARB) two weeks later. Other diagnostic 
criteria were tuberculosis, meningitis, and 
computerized tomography and microbial studies. 
Miliary or extrapulmonary tuberculous cerebrospinal 
fluid was analyzed. The diagnosis of ATDH is based 
on clinical findings of high ALT and laboratory 
results. he / she had one of the following, especially 
the ATDH diagnosed that there was no obvious 
reason for liver function tests: 
 
Serum is 5 times above the normal limit of ALT (40 
U / L) and the absence of hepatitis symptoms and 
symptoms. Clinical hepatotoxicity was diagnosed if 
ALT ATDH symptoms were elevated, including 
vomiting, nausea, jaundice and weakness. Patients 
with ALT at high baseline were not included in the 
study. For each drug induced anti-tuberculous 
hepatitis case, without ATDH three patients were 
selected randomly as controls. Medical history, 
demographic characteristics,  HIV, incarceration, 
HCV drug dependence, HBV serologic, underlying 
diseases, TB treatment in both cases (ATDH patients) 
and side effects of medication and other health 
problems during control. The data were analyzed in 
the SPSS 17 version and with full fishery tests and 
chi-square. In this study, TB patients are followed for 
12 months (months, 3, 6, and 12) after treatment (6 
months minimum) and after treatment completion. 
ATDH and follow-up were recorded throughout the 
treatment period. 
 
RESULTS: 
By the NPT regime, 792 cases were treated. Male 
were 489 (61.8%) and female were 304 (37.92%). 
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During the treatment and follow-up period, a total of 
90 patients (5%), including females 66 (33.08%) and 
(66.92%)133 were male, 43.2 years was the mean age 
and 9.5 SD were recorded as ATDH. In two hundred 
(60.98%) patients, in the first two months ATDH 
occurred after treatment. With ATDH associated four 
deaths occurs only.  
 
 
 
 
Previous viral infections (B and C) were found in 78 cases (39.09%), with incarnation and intravenous drug 
injection in the majority (78%). Other results of non-ATDH (control) and ATDH (case) are given in Table-I. 
 
DISCUSSION: 
In this age of work, they were considered to inject 
risk factors for smoking, drug dependence for 
ADHD, imprisonment, alcohol consumption, viral 
hepatitis and HIV coinfection. The rate of HCV 
infection was statistically significant (p = 0.0001, 
OR: 14.2) in patients without ATDH ATDH, in fact, 
HCV patients were higher than those who were 
negative for HCV risk. Similar findings were found 
in other studies. As in other studies, we found a 
relationship between HBsAg positivity and 
hepatotoxicity development. In fact, the effect of 
HBV infection is much less than the effect of HCV. 
This can be attributed to routine inoculation against 
HBV since it is not possible to achieve a full effect of 
each risk factor. As a result, it was difficult to 
establish a close relationship with different 
parameters, such as associating hepatotoxicity with 
these parameters. Moreover, since most of the 
participants in our study were weak, it was difficult 
to see the relationship between malnutrition and 
hepatotoxicity. Because the study takes place only in 
a health center located on the eastern shore, the 
economic status of the whole country and the 
representation of the ethnic group may be a problem. 
 
CONCLUSION: 
As in previous studies, smoking has been considered 
as risk factors for ADHD, including injecting drug 
dependence, incarceration, viral hepatitis, alcohol 
consumption and HIV coinfection, HCV infection, 
infection. By IVDU and HIV, We recommend that 
patients who are infected with HIV, HCV, and who 
are dependent on IVD should undergo an initial liver 
function screening test and be followed closely with 
the follow-up tests during treatment. We also 
recommend further study to investigate why these 
risk factors contribute to the hepatotoxicity 
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development and to elaborate in detail the risk factors 
not addressed in this study. 
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